Preservative-Free Tacrolimus Ophthalmic Composition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic conjunctivitis, such as topical steroids, are ineffective for long-term management and come with significant side effects, while alternatives like cyclosporin are not suitable for atopic keratoconjunctivitis, and existing tacrolimus formulations like TALYMUS cause unacceptable eye irritation.
Innovation Solution
A preservative-free tacrolimus composition with a concentration of 0.01% to 1% tacrolimus, sterilized by gamma irradiation, is developed, with a pH of 6 to 9 and micronized to a particle size of 0.1 to 10 microns, providing effective relief for ocular redness and itchiness without harming the innate immune system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical steroids are used to manage allergic conjunctivitis, then ocular inflammation is suppressed, but side effects such as infection, cataract, and glaucoma increase
Solution Approach 1:
The patent changes the active ingredient from topical steroids to tacrolimus (a calcineurin inhibitor), fundamentally altering the pharmacological mechanism while maintaining anti-inflammatory efficacy. This parameter change allows suppression of ocular inflammation through a different pathway that does not carry the same risks of steroid-induced complications such as cataracts and glaucoma
Solution Approach 2:
The patent employs preservative-free formulation with single-use vials, eliminating the need for long-term preservative exposure that could contribute to toxic anterior segment syndrome (TASS). Each vial is sterile and disposable, reducing cumulative exposure to harmful preservatives while maintaining sterility throughout the treatment course
2Reliability
If TALYMUS (0.1% tacrolimus) is used for AKC and VKC, then allergic symptoms are relieved, but eye burning and irritation occur in 40% of patients
Solution Approach 1:
The patent modifies multiple parameters of the tacrolimus formulation: reducing particle size through micronization (0.1-10 microns), adjusting pH to physiological range (6.5-7.5), optimizing osmolality (280-320 mOsm/kg), and selecting specific excipients. These parameter changes collectively reduce ocular irritation while preserving the immunosuppressive efficacy against allergic symptoms
Solution Approach 2:
The patent uses a composite formulation system combining tacrolimus with specific excipients including hydroxypropyl methylcellulose (HPMC) as a viscosifier, phosphates as buffers, and glycerin as an osmolality adjuster. This composite material approach creates a synergistic formulation that enhances drug delivery and reduces irritation compared to simple tacrolimus solutions
3Reliability
If preservatives are added to multidose containers, then microbial contamination is prevented, but ocular irritation and toxicity increase
Solution Approach 1:
The patent employs preservative-free single-use vials as the primary delivery system. Each vial is sterile-filled and sealed, eliminating the need for preservatives entirely. This disposable approach prevents microbial contamination through physical sterility barriers rather than chemical preservatives, avoiding preservative-induced ocular surface toxicity and irritation
Solution Approach 2:
The patent introduces an intermediary sterile barrier system consisting of sterile filters and sealed vial closures that prevent microbial contamination without requiring preservative chemicals. This intermediary physical barrier protects against infection while avoiding the harmful effects of preservative exposure to the ocular surface
4Reliability
If particle size is reduced to improve drug delivery, then ocular surface penetration increases, but manufacturing complexity increases
Solution Approach 1:
The patent specifies a micronized particle size range of 0.1-10 microns for tacrolimus, optimizing ocular surface penetration and dissolution. This parameter is achieved through standard micronization processes that balance enhanced drug delivery with manufacturability, avoiding the need for more complex nanotechnology while still improving bioavailability compared to larger particles
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively suppresses the adaptive immune system, reducing inflammatory responses and providing prolonged ocular surface residence time, thus addressing the limitations of existing treatments with improved safety and efficacy.
Implementation Method 1
the tacrolimus composition or tacrolimus powder used to create the composition is sterilized by gamma irradiation. In certain embodiments, the gamma irradiation does not degrade the tacrolimus molecules.
Data Source
AI summary
The subject invention pertains to tacrolimus compositions and a method for the treatment of symptoms of allergic conjunctivitis or keratoconjunctivitis, including, for example, ocular redness and ocular itchiness. The composition is preservative free and can be dispensed in a multidose container.